Teva loses plea against GSK’s $235m ‘skinny label’ win
16-05-2023
AstraZeneca prevails in GSK royalties row at UK High Court
06-04-2023
23-05-2023
MAXSHOT.PL / Shutterstock.com
Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.
Last week (May 15), the Supreme Court denied certiorari in GlaxoSmithKline v Teva Pharms USA (GSK v Teva), locking in the US Court of Appeals for the Federal Circuit’s second panel decision which held that Teva’s attempted section viii carve-out of an indication covered by a patented method of use was not ‘skinny’ enough to avoid being liable for infringement.
Although the court did not state why certiorari was denied—as is common—the order list stated that Justice Brett Kavanaugh would grant the petitions for certiorari. One possible reason that the court believes that certiorari is not ripe is that Teva’s affirmative defence of equitable estoppel, ie, if GSK’s representations to the US Food and Drug Administration (FDA) were at odds with its enforcement efforts in this case, still needs to be considered on remand. The opinions from the Federal Circuit concurring and dissenting from the denial for the petition for rehearing en banc have left copious notes for the district court to consider on remand regarding equitable estoppel.
While the district court will now have to consider the issues of equitable estoppel on remand, there are still several other effects from GSK v Teva that we see in other district court cases, at the FDA, and for biosimilars.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
GSK, Teva, Supreme Court, patent infringement, FDA, Federal Court, biosimilars, orphan drug, innovation, Hatch-Waxman, skinny labels